

1. Sales 2004 and 2003

January – September	2004	2003	% change	
	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals	16,132	14,192	+14	+17
Roche Prescription	10,523	9,584	+10	+12
Genentech Prescription	3,287	2,466	+33	+43
Chugai Prescription	2,322	2,142	+8	+7
Diagnostics	5,763	5,382	+7	+8
Continuing Businesses ¹	21,895	19,574	+12	+14
Consumer Health (OTC)	1,320	1,306	+1	+2
Vitamins and Fine Chemicals ²	-	2,260	-100	-100
Roche Group	23,215	23,140	+0	+2

¹ Continuing businesses includes the core Pharmaceuticals and Diagnostics businesses. The Consumer Health (OTC) business and the Vitamins and Fine Chemicals business are reported as discontinuing businesses.

² Consolidated until 30 September 2003

2. Quarterly local sales growth by Division in 2003 and 2004

	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003	Q2 2004 vs. Q2 2003	Q3 2004 vs. Q3 2003
Pharmaceuticals	+21	+18	+15	+17
Roche Prescription	+24	+16	+10	+9
Genentech Prescription	+21	+29	+46	+54
Chugai Prescription	+13	+12	+4	+7
Diagnostics	+12	+10	+9	+6
Continuing Businesses	+18	+15	+13	+14

3. Core Division's quarterly sales in 2003 and 2004

CHF millions	Q4 2003	Q1 2004	Q2 2004	Q3 2004
Pharmaceuticals	5,589	5,217	5,430	5,485
Roche Prescription	3,659	3,546	3,494	3,483
Genentech Prescription	916	923	1,129	1,235
Chugai Prescription	1,014	748	807	767
Diagnostics	2,027	1,908	1,971	1,884
Continuing Businesses	7,616	7,125	7,401	7,369

4. Top 20 prescription medicines sales¹ and local growth² in the first nine months of 2004: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	2,501	31%	1,529	18%	136	135%	836	54%
Neo Recormon/Epogin	1,548	1%	-	-	573	-1%	975	3%
Herceptin	1,057	25%	446	18%	76	12%	535	36%
Cellcept	1,056	12%	481	4%	17	21%	558	21%
Rocephin	981	2%	589	9%	37	-3%	355	-8%
Pegasys	880	93%	348	42%	48	-	484	136%
Xenical	456	-1%	76	-26%	-	-	380	7%
Avastin	452	-	447	-	-	-	5	
Xeloda	388	-1%	135	-33%	16	219%	237	30%
Nutropin/Protoprin	335	9%	326	9%	-	-	9	-2%
Kytril	334	8%	134	7%	89	-4%	111	21%
Copegus	296	118%	170	58%	-	-	126	392%
Dilatrend	286	0%	-	-	-	-	286	0%
Roaccutan/Accutane	253	-35%	89	-57%	-	-	164	-8%
Pulmozyme	252	9%	144	11%	-	-	108	6%
Cymevene/Valcyte	246	21%	137	16%	-	-	109	28%
Tamiflu	237	107%	47	208%	84	0%	106	622%
Neutrogen	237	0%	-	-	237	0%	-	-
Activase/TNKase	211	7%	186	7%	-	-	25	6%
Madopar	186	4%	-	-	14	2%	172	4%
New products not covered in Top 20								
Xolair	161	1804%	161	1804%	-	-	-	-
Fuzeon	121	411%	75	306%	-	-	46	868%
Raptiva	48	-	48	-	-	-	-	-
Renagel	33	149%	-	-	33	149%	-	-
Evista	23	-	-	-	23	-	-	-

¹ Roche Rx, Genentech Rx and Chugai Rx combined

² versus 2003

5. Top 20 prescription medicines quarterly local sales growth¹ in 2003 and 2004

	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003	Q2 2004 Vs. Q2 2003	Q3 2004 vs. Q3 2003
MabThera/Rituxan	30%	33%	29%	31%
NeoRecormon/Epogin	7%	5%	0%	-1%
Herceptin	19%	27%	24%	25%
Cellcept	20%	23%	14%	0%
Rocephin	22%	4%	-5%	8%
Pegasys	466%	207%	82%	48%
Xenical	-11%	1%	-2%	-2%
Avastin	-	-	-	-
Xeloda	3%	-11%	-11%	19%
Nutropin/Protropin	9%	11%	10%	7%
Kytril	3%	28%	1%	-1%
Copegus	-	358%	110%	43%
Dilatrend	17%	14%	-4%	-10%
Roaccutan/Accutane	-25%	-33%	-17%	-59%
Pulmozyme	26%	15%	2%	11%
Cymevene/Valcyte	5%	38%	13%	14%
Tamiflu	207%	-1%	133%	-
Neutrogen	-6%	6%	-3%	-1%
Activase/TNKase	-15%	-1%	8%	13%
Madopar	4%	6%	3%	3%

¹ Roche Rx, Genentech Rx and Chugai Rx combined

6. Prescription medicines quarterly local sales growth¹ US in 2003 and 2004

	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003	Q2 2004 vs. Q2 2003	Q3 2004 vs. Q3 2003
MabThera/Rituxan	22%	21%	16%	17%
NeoRecormon/Epogin	-	-	-	-
Herceptin	11%	16%	19%	19%
Cellcept	21%	18%	12%	-15%
Rocephin	50%	13%	-4%	20%
Pegasys	1068%	166%	26%	1%
Xenical	-13%	-14%	-29%	-36%
Avastin	-	-	-	-
Xeloda	-31%	-49%	-44%	7%
Nutropin/Protropin	9%	11%	10%	7%
Kytril	-3%	43%	-6%	-6%
Copegus	-	270%	47%	-2%
Dilatrend	-	-	-	-
Roaccutan/Accutane	-36%	-46%	-31%	-
Pulmozyme	36%	16%	3%	14%
Cymevene/Valcyte	-5%	41%	4%	6%
Tamiflu	355%	-	246%	-
Neutrogen	-	-	-	-
Activase/TNKase	-7%	-4%	10%	15%
Madopar	-	-	-	-

¹ Roche Rx and Genentech Rx combined

7. Prescription medicines quarterly local sales growth Japan¹ in 2003 and 2004

	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003	Q2 2004 vs. Q2 2003	Q3 2004 vs. Q3 2003
MabThera/Rituxan	153%	177%	123%	120%
NeoRecormon/Epogin	2%	7%	-5%	-2%
Herceptin	16%	28%	3%	11%
Cellcept	20%	34%	14%	17%
Rocephin	22%	3%	-11%	1%
Pegasys	-	-	-	-
Xenical	-	-	-	-
Avastin	-	-	-	-
Xeloda	-	-	484%	48%
Nutropin/Protropin	-	-	-	-
Kytril	8%	4%	-8%	-6%
Copegus	-	-	-	-
Dilatrend	-	-	-	-
Roaccutan/Accutane	-	-	-	-
Pulmozyme	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Tamiflu	117%	6%	-	-
Neutrogin	-6%	6%	-3%	-1%
Activase/TNKase	-	-	-	-
Madopar	3%	4%	0%	2%

¹ Chugai Rx

8. Prescription medicines quarterly local sales growth Europe/Rest of World¹ in 2003 and 2004

	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003	Q2 2004 vs. Q2 2003	Q3 2004 vs. Q3 2003
MabThera/Rituxan	42%	56%	52%	55%
NeoRecormon/Epogin	14%	4%	4%	0%
Herceptin	31%	39%	33%	34%
Cellcept	21%	29%	16%	17%
Rocephin	-9%	-8%	-6%	-10%
Pegasys	245%	236%	130%	87%
Xenical	-11%	6%	7%	8%
Avastin	-	-	-	-
Xeloda	27%	34%	27%	28%
Nutropin/Protropin	-4%	-7%	3%	-2%
Kytril	8%	31%	21%	12%
Copegus	-	757%	367%	275%
Dilatrend	17%	14%	-4%	-10%
Roaccutan/Accutane	-12%	-13%	-3%	-9%
Pulmozyme	10%	13%	1%	5%
Cymevene/Valcyte	12%	32%	27%	25%
Tamiflu	154%	191%	278%	-
Neutrogen	-	-	-	-
Activase/TNKase	-49%	39%	-4%	-3%
Madopar	3%	6%	3%	3%

¹ Roche Rx

9. Top Prescription medicines quarterly sales^{1,2} in 2003 and 2004

CHF millions	Q4 2003	Q1 2004	Q2 2004	Q3 2004
MabThera/Rituxan	781	782	842	877
NeoRecormon/Epogin	545	489	531	528
Herceptin	315	328	356	373
Cellcept	357	369	350	337
Rocephin	368	369	305	307
Pegasys	253	289	295	296
Xenical	151	146	165	145
Avastin	-	48	169	235
Xeloda	111	115	128	145
Nutropin/Protropin	112	109	116	110
Kytril	119	109	111	114
Copegus	81	102	97	97
Dilatrend	106	104	96	86
Roaccutan/Accutane	113	116	94	43
Pulmozyme	88	84	82	86
Cymevene/Valcyte	69	86	79	81
Tamiflu	317	108	19	110
Neutrogen	84	76	80	81
Activase/TNKase	68	63	72	76
Madopar	63	61	63	62
New products not covered in Top 20				
Xolair	25	38	55	68
Fuzeon	24	31	47	43
Raptiva	2	8	17	23
Renagel	13	11	11	11
Evista	-	-	17	6

¹ Roche Rx, Genentech Rx and Chugai Rx combined

10. Prescription medicines quarterly sales¹ in US in 2003 and 2004

CHF millions	Q4 2003	Q1 2004	Q2 2004	Q3 2004
MabThera/Rituxan	523	484	514	531
NeoRecormon/Epogin	-	-	-	-
Herceptin	140	136	151	159
Cellcept	186	176	158	147
Rocephin	218	219	179	191
Pegasys	126	127	109	112
Xenical	35	27	29	20
Avastin	-	48	169	230
Xeloda	36	36	44	55
Nutropin/Protropin	109	106	113	107
Kytril	48	46	42	46
Copegus	60	64	53	53
Dilatrend	-	-	-	-
Roaccutan/Accutane	49	53	39	-3
Pulmozyme	53	48	46	50
Cymevene/Valcyte	37	51	42	44
Tamiflu	166	-8	8	47
Neutrogen	-	-	-	-
Activase/TNKase	58	56	63	67
Madopar	-	-	-	-
New products not covered in Top 20				
Xolair	25	38	55	68
Fuzeon	18	20	30	25
Raptiva	2	8	17	23
Renagel	-	-	-	-
Evista	-	-	-	-

¹ Roche Rx and Genentech Rx combined

11. Prescription medicines quarterly sales¹ in Japan in 2003 and 2004

CHF millions	Q4 2003	Q1 2004	Q2 2004	Q3 2004
MabThera/Rituxan	51	39	48	49
NeoRecormon/Epogin	232	171	203	199
Herceptin	28	22	26	28
Cellcept	6	5	6	6
Rocephin	16	11	14	12
Pegasys	2	8	18	22
Xenical	-	-	-	-
Avastin	-	-	-	-
Xeloda	6	4	6	6
Nutropin/Protropin	-	-	-	-
Kytril	39	26	32	31
Copegus	-	-	-	-
Dilatrend	-	-	-	-
Roaccutan/Accutane	-	-	-	-
Pulmozyme	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Tamiflu	134	87	-3	-
Neutrogen	84	76	80	81
Activase/TNKase	-	-	-	-
Madopar	6	4	5	5
New products not covered in Top 20				
Xolair	-	-	-	-
Fuzeon	-	-	-	-
Raptiva	-	-	-	-
Renagel	13	11	11	11
Evista	-	-	17	6

¹ Chugai Rx

12. Prescription medicines quarterly sales in Europe/Rest of World¹ in 2003

CHF millions	Q4 2003	Q1 2004	Q2 2004	Q3 2004
MabThera/Rituxan	207	259	280	297
NeoRecormon/Epogin	313	318	328	329
Herceptin	147	170	179	186
Cellcept	165	188	186	184
Rocephin	134	139	112	104
Pegasys	125	154	168	162
Xenical	116	119	136	125
Avastin	-	-	-	5
Xeloda	69	75	78	84
Nutropin/Protropin	3	3	3	3
Kytril	32	37	37	37
Copegus	21	38	44	44
Dilatrend	106	104	96	86
Roaccutan/Accutane	64	63	55	46
Pulmozyme	35	36	36	36
Cymevene/Valcyte	32	35	37	37
Tamiflu	17	29	14	63
Neutrogen	-	-	-	-
Activase/TNKase	10	7	9	9
Madopar	57	57	58	57
New products not covered in Top 20				
Xolair	-	-	-	-
Fuzeon	6	11	17	18
Raptiva	-	-	-	-
Renagel	-	-	-	-
Evista	-	-	-	-

¹ Roche Rx